<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01911546</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001AUS200T</org_study_id>
    <nct_id>NCT01911546</nct_id>
  </id_info>
  <brief_title>Role of Everolimus in Highly Sensitized Patients</brief_title>
  <official_title>A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Everolimus for the Prevention of BK and CMV Viremia in HLA Sensitized Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph Kahwaji, MD, MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A growing number of patients on the kidney transplant waiting list are broadly human
      leukocyte antigen (HLA) sensitized (HS). These patients are unlikely to have a compatible
      donor. Therefore they wait longer and have increased morbidity and mortality. Desensitization
      with intravenous immune globulin (IVIG) and rituximab with alemtuzumab induction improves
      transplant rates and achieves good allograft outcomes. However, HS patients are at risk for
      viral infections after transplant. We have previously shown an increased incidence of BKV
      infections after desensitization with HS patients having higher peak viral loads.
      Cytomegalovirus (CMV) and polyomavirus BK (BKV) infections place HS renal transplant
      recipients at particular risk. Allograft rejection is associated with both CMV and BKV
      infection. This is of particular concern for HS patients as they are at an increased risk of
      rejection at baseline. Furthermore, the frequent development of leukopenia after
      transplantation often requires the CMV prophylactic agent to be discontinued along with
      lowering immunosuppression. This increases the risk of CMV infection and allograft rejection.

      Everolimus was approved for rejection prophylaxis in combination with calcineurin inhibitors
      (CNI). CNI used in the study that led to drug's approval was cyclosporine. There are several
      trials nearing it's completion that utilize low dose tacrolimus instead. In 2012 Novartis
      published data from several trials showing superior outcomes using everolimus + low dose
      tacrolimus. This combination is currently approved in EU. It is also a combination that is
      standard of care (SOC) at our center for patients on everolimus.

      This study aims to demonstrate that use of everolimus as part of a maintenance
      immunosuppression regimen may decrease viral infections without lowering overall
      immunosuppression thus improving allograft function and survival.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">January 19, 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Polyoma BK Viremia Patients</measure>
    <time_frame>12 months</time_frame>
    <description>Patients will be monitored at regular interval for the development of Polyomavirus Viremia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of CMV Viremia</measure>
    <time_frame>12 Months</time_frame>
    <description>The number of patients with CMV viremia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Antibody Mediated Rejection (ABMR)</measure>
    <time_frame>6 months</time_frame>
    <description>Protocol biopsies were obtained at T0 and 6 months post transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cell Mediated Rejection (CMR)</measure>
    <time_frame>6 months</time_frame>
    <description>Patients will be monitored for any episodes of CMR.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Highly-sensitized Kidney Transplant Recipients</condition>
  <arm_group>
    <arm_group_label>everolimus + low-dose tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving everolimus will be on low dose tacrolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus + low-dose tacrolimus</intervention_name>
    <description>Patients are supplied everolimus (Zortress) + prograf</description>
    <arm_group_label>everolimus + low-dose tacrolimus</arm_group_label>
    <other_name>zortress + prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Recipient of a deceased or living donor kidney allograft

          2. Patients must have undergone desensitization with IVIG and rituximab with or without
             plasma exchange prior to transplant or be administered IVIG and rituximab
             peri-operatively.

          3. Age 18 and over

          4. Able to understand and provide informed consent

        Exclusion Criteria:

        Recipients of a dual simultaneous kidney/liver, kidney/heart, kidney/lung transplant 2.
        Pregnant or lactating females 3. Patients with a platelet count &lt; 100,000/mm3 at time of
        randomization 4. Patients with an absolute neutrophil count &lt; 1,500/mm3 or a white blood
        cell count of &lt;3,000/mm3 at time of randomization 5. Patients who have an abnormal liver
        profile such as ALT, AST, Alkaline Phosphatase, or total bilirubin &gt; 3 times the upper
        limit of normal (ULN) at time of randomization 6. Patients with severe total
        hypercholesterolemia (&gt; 350 mg/dL; &gt; 9 mmol/L) or total hypertriglyceridemia (&gt; 500 mg/dL;
        &gt; 5.6 mmol/L). Patients on lipid lowering treatment with controlled hyperlipidemia are
        acceptable.

        7. History of hypersensitivity to any of the study drugs or to drugs of similar chemical
        classes 8. Patients being treated with drugs that are strong inducers or inhibitors of
        cytochrome P450 3A4 9. Patients with a clinically significant systemic infection within 30
        days prior to transplant 9 10. Patients who have any surgical or medical condition, such as
        severe diarrhea, active peptic ulcer disease, or uncontrolled diabetes mellitus, which in
        the opinion of the investigator, might significantly alter the absorption, distribution,
        metabolism and/or excretion of study medication.

        11. Patients with a history of coagulopathy or medical condition that would require
        long-term anticoagulation therapy after transplantation, unless the condition would permit
        a two week interruption in therapy before and after allograft biopsy. (Treatment with low
        dose aspirin is allowed.) 12. Women of childbearing potential who are either pregnant,
        lactating, planning to become pregnant during this trial, or with a positive serum or urine
        pregnancy test. Women of childbearing potential must be willing to agree to contraceptive
        practices.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2013</study_first_submitted>
  <study_first_submitted_qc>July 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2013</study_first_posted>
  <results_first_submitted>August 9, 2017</results_first_submitted>
  <results_first_submitted_qc>November 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 7, 2017</results_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Joseph Kahwaji, MD, MPH</investigator_full_name>
    <investigator_title>former transplant nephrologist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Highly HLA Sensitized Patients with End Stage Renal Disease Receiving Deceased Donor or Living Donor kidney transplant were enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Everolimus + Low-dose Tacrolimus</title>
          <description>20 patients received everolimus with low dose tacrolimus.
Everolimus + low-dose tacrolimus: Patients are supplied everolimus (Zortress) + prograf</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Everolimus was discontinued</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 20 patients were enrolled in this clinical trial.</population>
      <group_list>
        <group group_id="B1">
          <title>Everolimus + Low-dose Tacrolimus</title>
          <description>Patients receiving everolimus will be on low dose tacrolimus.
everolimus + low-dose tacrolimus: Patients are supplied everolimus (Zortress) + prograf</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>patients</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.65" spread="11.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cause of ESRD</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Alport Syndrome</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Congenital</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>FSGS</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HTN</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lupus</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PCKD</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Post-Infectious Glomerulonephropathy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown Etiology</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Polyoma BK Viremia Patients</title>
        <description>Patients will be monitored at regular interval for the development of Polyomavirus Viremia.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Low-dose Tacrolimus</title>
            <description>20 patients received everolimus with low dose tacrolimus.
Everolimus + low-dose tacrolimus: Patients are supplied everolimus (Zortress) + prograf</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Polyoma BK Viremia Patients</title>
          <description>Patients will be monitored at regular interval for the development of Polyomavirus Viremia.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of CMV Viremia</title>
        <description>The number of patients with CMV viremia</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Low-dose Tacrolimus</title>
            <description>20 patients received everolimus with low dose tacrolimus.
Everolimus + low-dose tacrolimus: Patients are supplied everolimus (Zortress) + prograf</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of CMV Viremia</title>
          <description>The number of patients with CMV viremia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Antibody Mediated Rejection (ABMR)</title>
        <description>Protocol biopsies were obtained at T0 and 6 months post transplant.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Low-dose Tacrolimus</title>
            <description>20 patients received everolimus with low dose tacrolimus.
Everolimus + low-dose tacrolimus: Patients are supplied everolimus (Zortress) + prograf</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Antibody Mediated Rejection (ABMR)</title>
          <description>Protocol biopsies were obtained at T0 and 6 months post transplant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Cell Mediated Rejection (CMR)</title>
        <description>Patients will be monitored for any episodes of CMR.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Low-dose Tacrolimus</title>
            <description>20 patients received everolimus with low dose tacrolimus.
Everolimus + low-dose tacrolimus: Patients are supplied everolimus (Zortress) + prograf</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Cell Mediated Rejection (CMR)</title>
          <description>Patients will be monitored for any episodes of CMR.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From transplant to 12 months post transplant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Everolimus + Low-dose Tacrolimus</title>
          <description>20 patients received everolimus with low dose tacrolimus.
Everolimus + low-dose tacrolimus: Patients are supplied everolimus (Zortress) + prograf</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath and Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nocardia Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <description>Swelling was seen in patient one month post transplant</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urine Leak</sub_title>
                <description>Urine leak occurred 2 weeks and 1 month post transplant</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Antibody Mediated Rejection and Thrombotic Microangiopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Antibody Mediated Rejection / FSGS /Small Bowel Obstruction/Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>General pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were a total of 20 patients enrolled into this clinical trial. Of the 20 patients, six patients were withdrawn.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Joseph Kahwaji, MD, MPH</name_or_title>
      <organization>Former: Cedars-Sinai Medical Center, Comprehensive Transplant Center</organization>
      <phone>310-423-2641</phone>
      <email>joseph.m.kahwaji@kp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

